Clinical trials: Recurrent Female Reproductive System Carcinoma
Endometrial Cancer
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
The primary objective of this study is to estimate whether the addition of trastuzumab to paclitaxel and carboplatin chemotherapy improves progression free survival when compared to paclitaxel and carboplatin alone in Uterine…
- Trial name
- NCT01367002
- Testing
- Carboplatin/Paclitaxel, Trastuzumab
- Where
- 20 sites in United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Ovarian Cancer, Ovary Neoplasm
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
A phase III prospective study with the primary objective to compare the efficacy and safety of HIPEC( Hyperthermic Intraperitoneal Chemotherapy).
- Conditions
- Ovarian Cancer, Ovary Neoplasm, Ovarian Neoplasms, Epithelial Ovarian Cancer
- Trial name
- HIPECOV (NCT03371693)
- Testing
- HIPEC, CRS, IVCT
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Zhongnan Hospital
Endometrial Cancer
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
This is an open-label, multi-center, single-arm, two-period Phase 2 study. The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with recurrent or…
- Trial name
- NCT03077698
- Testing
- Sodium Cridanimod, progestin therapy
- Where
- 25 sites in United States
- Volunteers
- 25 people
- Sponsor
- Xenetic Biosciences, Inc.
Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Akt inhibitor MK2206 is a drug that may stop cancer cells from growing by blocking a protein called protein kinase B (AKT) inside the cell.
- Conditions
- Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01283035
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Neoplasms, Endometrial Cancer
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy.
- Trial name
- NCT07578649
- Testing
- PF-08634404, Pembrolizumab, Standard of Care Chemotherapy
- Where
- 43 sites in United States, Australia and 2 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a period of improvement (relapsed) or that remains despite treatment…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT06483048
- Testing
- Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Endometrial Neoplasms
Lenvatinib in Second Line Endometrial Carcinoma
The primary objective of this multicenter, randomized phase II trial is to assess the efficacy, as measured by progression-free survival (PFS), of lenvatinib compared to doxorubicin in advanced or recurrent endometrial cancer.
- Trial name
- NCT03005015
- Testing
- Lenvatinib, Doxorubicin
- Where
- Switzerland
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL2 (NCT01891344)
- Testing
- Oral rucaparib
- Where
- 75 sites in United States, Australia and 4 more
- Volunteers
- 491 people
- Sponsor
- pharmaand GmbH
Ovarian Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with peripheral stem cell transplantation may allow the doctor to give higher…
- Trial name
- NCT00003413
- Testing
- filgrastim, carmustine, cisplatin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Maryland, Baltimore
Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
This phase I trial studies the side effects and best dose of activated T-cell therapy when given together with low-dose aldesleukin and sargramostim in treating patients with ovarian, fallopian tube, or primary peritoneal cancer…
- Conditions
- Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02470559
- Testing
- Aldesleukin, HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Fallopian Tube Cancer, Ovarian Cancer
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Progesterone can cause the growth of ovarian epithelial cancer , primary peritoneal cancer, or fallopian tube cancer.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00459290
- Testing
- mifepristone
- Where
- 22 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Cancer
Study of Ramucirumab in Ovarian Cancer
The purpose of this study is to determine if ramucirumab given as monotherapy is effective in the treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT00721162
- Testing
- Ramucirumab
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Endometrial Cancer
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with…
- Conditions
- Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Melanoma (Skin)
- Trial name
- NCT00526149
- Testing
- BI 2536, high performance liquid chromatography, mass spectrometry
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cervical Cancer
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002813
- Testing
- cisplatin, vinorelbine tartrate
- Where
- 9 sites in United States
- Volunteers
- 62 people
- Sponsor
- Gynecologic Oncology Group
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
This phase I trial investigates the side effects and best dose of abexinostat and palbociclib when given together with fulvestrant in treating patients with breast or gynecologic cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04498520
- Testing
- Abexinostat Tosylate, Fulvestrant, Palbociclib
- Sponsor
- Pamela Munster
Fallopian Tube Cancer, Ovarian Cancer
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
This was a Phase 1, non-randomized, open-label, multicenter study of the ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine administered with the granulocyte macrophage-colony stimulating factor (GM-CSF) sargramostim in patients with NY-ESO-1…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00803569
- Testing
- ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine, Sargramostim
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Ludwig Institute for Cancer Research
Colorectal Cancer, Lung Cancer
Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers
RATIONALE: A disease management program may be more effective than standard therapy in improving quality of life and controlling symptoms in patients with cancer.
- Conditions
- Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- NCT00684801
- Testing
- questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 605 people
- Sponsor
- Case Comprehensive Cancer Center
Epithelial Ovarian Cancer
Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer
Randomized clinical trial to asses the efficacy of closed abdomen hyperthermia intraperitoneal chemotherapy with paclitaxel in ovarian cancer.
- Trial name
- hipecova (NCT02681432)
- Testing
- HIPEC, No HIPEC
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- PEDRO VILLAREJO CAMPOS
Ovarian Neoplasms, Recurrent Ovarian Carcinoma
Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer
This is a prospective, multicenter, Phase II study aimed at defining the activity and safety of SBRT in MPR-OC. Clinical and imaging data as well as SBRT parameters would be analyzed with the aim to identify potential predictors…
- Conditions
- Ovarian Neoplasms, Recurrent Ovarian Carcinoma, Oligometastatic Disease
- Trial name
- MITO-RT3/RAD (NCT04593381)
- Testing
- Stereotactic body radiotherapy
- Where
- 14 sites in Italy
- Volunteers
- 376 people
- Sponsor
- Gemelli Molise Hospital
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
This randomized clinical trial is studying the side effects of oregovomab and to see how well it works with or without cyclophosphamide in treating patients with stage III or stage IV ovarian epithelial cancer, fallopian tube…
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage III Ovarian Cancer
- Trial name
- NCT00551265
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Oregovomab
- Where
- United States
- Sponsor
- Gynecologic Oncology Group